Are we ready for what is coming? Full text here: The Endless Frontier? The Recent Upsurge of R&D Productivity in Pharmaceuticals https://t.co/NsccMX1qrZ
— Luca Pani (@luca__pani) June 21, 2019
In 2012, Ivacaftor developed by Vertex became the first drug to treat the cause rather than symptoms of cystic fibrosis. Now the structure of the drug bound to its target, the ion channel CFTR, has finally been cracked by the Chen lab at Rockefeller. https://t.co/uXIR0mkS6A pic.twitter.com/8JD8Oke2Cx
— Ash Jogalekar (@curiouswavefn) June 20, 2019
Congrats to associate editor @shsternberg for this cool paper, which he inexplicably chose to publish in @nature “Transposon-encoded CRISPR–Cas systems direct RNA-guided DNA integration” https://t.co/2Te6mntgQd
— The CRISPR Journal (@CRISPRjournal) June 13, 2019
Therapeutic developments for Duchenne muscular dystrophy
— Bertrand Delsuc (@BertrandBio) June 7, 2019
nice box1 explanationhttps://t.co/SmpyZbZNqx pic.twitter.com/iIqlBbqp27
Trends in clinical success rates and therapeutic focus https://t.co/ORRWXlBC4b - a new analysis published today indicates success rates from phase III to launch have improved since the start of the decade while phase II success rates have remained static pic.twitter.com/Tln4YZybIJ
— Nature Rev Drug Disc (@NatRevDrugDisc) May 8, 2019
A chemical inhibitor of the CRISPR–Cas9 gene-editing tool could allow researchers to switch editing on and off in living cells. #ResearchHighlight https://t.co/wcdwl5nU7J
— nature (@nature) May 6, 2019
Review on a target of many deals on past months: NLRP3
— Bertrand Delsuc (@BertrandBio) April 29, 2019
The NLRP3 inflammasome: molecular activation and regulation to therapeuticshttps://t.co/hVzxjCraPa pic.twitter.com/bOdm5VJi2J
RSS Feed
